Last reviewed · How we verify
Joincare Pharmaceutical Group Industry Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
3 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| JKN2301 Dry Suspension | JKN2301 Dry Suspension | phase 3 | ||||
| JKN2401 Injection | JKN2401 Injection | phase 3 | GLP-1 receptor agonist | GLP-1R | Endocrinology / Diabetes |
Therapeutic area mix
- Endocrinology / Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Amsterdam UMC, location VUmc · 1 shared drug class
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · 1 shared drug class
- Beijing Chao Yang Hospital · 1 shared drug class
- Beijing Dongfang Biotech Co., Ltd. · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Joincare Pharmaceutical Group Industry Co., Ltd:
- Joincare Pharmaceutical Group Industry Co., Ltd pipeline updates — RSS
- Joincare Pharmaceutical Group Industry Co., Ltd pipeline updates — Atom
- Joincare Pharmaceutical Group Industry Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Joincare Pharmaceutical Group Industry Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/joincare-pharmaceutical-group-industry-co-ltd. Accessed 2026-05-17.